3.2 Which Specific Hormones You Take Makes All The Difference

Progesterone vs. Progestin

A progestin is a hormone that's very similar to the progesterone your body makes. The Women's Health Initiative study observed increased risks for breast cancer in women taking a progestin called medroxyprogesterone. Women who took both horse estrogens and medroxyprogesterone in the study had slightly higher risk for breast cancer.

Oddly, women in the Women's Health Initiative study who took only the horse estrogens, without medroxyprogesterone, did not have an increased risk for breast cancer.

Several studies have looked at women who have taken estradiol and progesterone, the hormones that are chemically identical to the estrogen and progesterone made by human females. In study after study, progesterone is found to be protective against breast cancer.

Women in France who took progesterone were shown in a study called "E3N Cohort" to have less breast cancer than women who took no hormones at all.


  1. Beral V; Million Women Study Collaborators.. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003 Aug 9;362(9382):419-27. Erratum in: Lancet. 2003 Oct 4;362(9390):1160. PubMed [citation] PMID: 12927427
  2. Cadeau C, Fournier A, Mesrine S, Clavel-Chapelon F, Fagherazzi G, Boutron-Ruault MC. Interaction between current vitamin D supplementation and menopausal hormone therapy use on breast cancer risk: evidence from the E3N cohort. Am J Clin Nutr. 2015 Oct;102(4):966-73. doi: 10.3945/ajcn.114.104323. Epub 2015 Sep 9. PubMed[citation] PMID: 26354532
  3. Regidor PA. Progesterone in Peri- and Postmenopause: A Review. Geburtshilfe Frauenheilkd. 2014 Nov;74(11):995-1002. PubMed [citation] PMID: 25484373, PMCID: PMC4245250
  4. Cottet V, Touvier M, Fournier A, Touillaud MS, Lafay L, Clavel-Chapelon F, Boutron-Ruault MC. Postmenopausal breast cancer risk and dietary patterns in the E3N-EPIC prospective cohort study. Am J Epidemiol. 2009 Nov 15;170(10):1257-67.doi: 10.1093/aje/kwp257. Epub 2009 Oct 14. PubMed [citation] PMID: 19828509
  5. [No authors listed] Progestagen-only treatment before menopause: increased riskof breast cancer. Prescrire Int. 2008 Dec;17(98):243. PubMed [citation] PMID:19422175
  6. Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol. 2008 Mar10;26(8):1260-8. doi: 10.1200/JCO.2007.13.4338. PubMed [citation] PMID: 18323549,PMCID: PMC2346534
  7. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005 Apr 10;114(3):448-54. PubMed [citation] PMID: 15551359
  8. Justenhoven C, Obazee O, Brauch H. The pharmacogenomics of sex hormonemetabolism: breast cancer risk in menopausal hormone therapy. Pharmacogenomics.2012 Apr;13(6):659-75. doi: 10.2217/pgs.11.144. Review. PubMed [citation] PMID:22515609
  9. Murkes D, Conner P, Leifland K, Tani E, Beliard A, Lundström E, Söderqvist G. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equineestrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2protein in healthy women. Fertil Steril. 2011 Mar 1;95(3):1188-91. doi:10.1016/j.fertnstert.2010.09.062. Epub 2010 Nov 10. PubMed [citation] PMID:21067727
  10. Murkes D, Lalitkumar PG, Leifland K, Lundström E, Söderqvist G. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo. Gynecol Endocrinol. 2012 Oct;28 Suppl 2:12-5. Epub 2012 Jul 27. PubMed [citation] PMID: 22834417
  11. Foidart JM, Colin C, Denoo X, Desreux J, Béliard A, Fournier S, de Lignières B. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril. 1998 May;69(5):963-9. PubMed [citation] PMID: 9591509
  12. McCarty MF. Androgenic progestins amplify the breast cancer risk associated with hormone replacement therapy by boosting IGF-I activity. Med Hypotheses. 2001Feb;56(2):213-6. PubMed [citation] PMID: 11425289
  13. L'Hermite M. Risks of estrogens and progestogens. Maturitas. 1990 Sep;12(3):215-46. Review. PubMed [citation] PMID: 2170823
  14. Costanian C, Edgell H, Ardern CI, Tamim H. Hormone therapy use in the Canadian Longitudinal Study on Aging: a cross-sectional analysis. Menopause. 2018Jan;25(1):46-53. doi: 10.1097/GME.0000000000000954. PubMed [citation] PMID:28796698
  15. Progesterone and breast cancer. Lange CA, Yee D. Women's health (London, England). 2008 Mar; 4(2): 151-162 PMC [article] PMCID: PMC4038907, PMID: 19072517, DOI: 10.2217/17455057.4.2.151
  16. Progesterone receptor modulates estrogen receptor-α action in breast cancer. Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA,Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD,D’Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C,Tilley WD, Carroll JS. Nature. 2015 Jul 8; 523(7560): 313-317 PMC [article] PMCID: PMC4650274, PMID: 26153859, DOI: 10.1038/nature14583
  17. Roles for estrogen and progesterone in breast cancer prevention. Jerry DJ. Breast Cancer Research. 2007 Mar 21; 9(2): 102PMC [article] PMCID: PMC1868925, PMID: 17381827, DOI: 10.1186/bcr1659